Market Currents
Watson Pharmaceuticals (WPI) expects to close its $5.9B acquisition of Swiss peer Actavis by...
-
Tuesday, October 16, 2012, 8:14 AM ETWatson Pharmaceuticals (WPI) expects to close its $5.9B acquisition of Swiss peer Actavis by early November after it yesterday received FTC permission for the deal, adding to EU authorization earlier this month. Under the conditions of the approval, Watson must sell 14 generic drugs to Par Pharmaceuticals (PRX) and four to Sandoz. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
